8-K: Applied Therapeutics Reports Q3 2024 Results, Anticipates Key Regulatory Decisions

Applied Therapeutics announced its third quarter 2024 financial results and provided updates on the regulatory progress of its lead drug candidate, govorestat, for the treatment of Classic Galactosemia and SORD Deficiency.

Summary

• Applied Therapeutics reported its financial results for the third quarter ended September 30, 2024.
• The company is focused on transitioning from a clinical-stage to a commercial organization.
• The New Drug Application (NDA) for govorestat for Classic Galactosemia is under FDA review with a PDUFA target action date of November 28, 2024.
• A Marketing Authorization Application (MAA) for govorestat for Classic Galactosemia is under review by the European Medicines Agency (EMA), with a decision expected in early Q1 2025.
• The company anticipates submitting an NDA for govorestat for SORD Deficiency under Accelerated Approval in early Q1 2025.
• Cash and cash equivalents and short-term investments totaled $98.9 million as of September 30, 2024, compared to $49.9 million at December 31, 2023.
• Research and development expenses for the quarter were $14.8 million, up from $10.8 million in the same period last year.
• General and administrative expenses were $15.0 million for the quarter, compared to $4.7 million in the same period last year.
• The net loss for the third quarter of 2024 was $68.6 million, or $0.48 per share, compared to a net loss of $42.4 million, or $0.47 per share, for the third quarter of 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the significant regulatory progress and strong cash position, but tempered by the substantial net loss and increased operating expenses. The company is making progress towards commercialization, but faces risks and uncertainties.

Positives

• The company has made significant progress in regulatory submissions for govorestat.
• The company has a strong cash position of $98.9 million.
• Govorestat has shown a rapid and sustained reduction in galactitol, with meaningful clinical benefits.
• Govorestat has a favorable safety profile.
• The company is preparing for its first commercial product launch.

Negatives

• The company experienced a significant net loss of $68.6 million for the quarter.
• Research and development expenses increased by $4.0 million compared to the same quarter last year.
• General and administrative expenses increased significantly by $10.3 million compared to the same quarter last year.
• The company's net loss per share remained relatively consistent at $0.48 compared to $0.47 in the same quarter last year, despite the increased loss.

Risks

• The company's future success is dependent on the approval of govorestat by regulatory agencies.
• There are risks associated with the development, marketing, and commercialization of product candidates.
• The company may need additional financing in the future.
• There are risks associated with intellectual property and competition.
• The company's financial results are subject to fluctuations.

Future Outlook

The company anticipates a transformational year ahead, with a focus on transitioning to a commercial organization and bringing govorestat to patients in 2025. They expect to submit an NDA for SORD Deficiency in early Q1 2025 and are awaiting regulatory decisions on the Classic Galactosemia applications.

Management Comments

• We are proud of the significant progress we've made this quarter as we prepare for a transformational year ahead, with a focus on transitioning from a clinical-stage company to a commercial organization.
• With regulatory submissions for govorestat underway in two rare disease indications of urgent unmet need, Classic Galactosemia and SORD Deficiency, we continue to thoughtfully execute our pre-launch initiatives.
• As we approach the final stages of the NDA review process for Classic Galactosemia in parallel with a near-term NDA submission for SORD Deficiency, we remain confident in the promise of govorestat and its ability to address the underlying mechanisms of both diseases.

Industry Context

This announcement is significant in the context of the rare disease biopharmaceutical industry, where companies focus on developing treatments for unmet medical needs. The progress of govorestat, particularly with the upcoming regulatory decisions, is a key milestone for Applied Therapeutics and could potentially set a new standard of care for Classic Galactosemia and SORD Deficiency.

Comparison to Industry Standards

• Applied Therapeutics is comparable to other clinical-stage biopharmaceutical companies focused on rare diseases, such as BioMarin Pharmaceutical and Ultragenyx Pharmaceutical.
• The company's focus on Aldose Reductase Inhibitors (ARIs) is a specific approach within the broader field of rare disease therapeutics.
• The company's cash position of $98.9 million is relatively strong for a company of its stage, but the high operating expenses and net loss are typical for companies in this phase of development.
• The regulatory timelines for govorestat are in line with industry standards for rare disease drug approvals, with the PDUFA date and EMA decision expected within typical timeframes.

Stakeholder Impact

• Shareholders will be impacted by the regulatory decisions and the company's financial performance.
• Employees will be impacted by the company's transition to a commercial organization.
• Patients with Classic Galactosemia and SORD Deficiency will be impacted by the potential approval of govorestat.
• Creditors will be impacted by the company's financial stability.

Next Steps

• The company will await the FDA decision on the NDA for govorestat for Classic Galactosemia by November 28, 2024.
• The company will await the EMA decision on the MAA for govorestat for Classic Galactosemia in early Q1 2025.
• The company will submit an NDA for govorestat for SORD Deficiency in early Q1 2025.
• The company will continue to execute pre-launch initiatives for govorestat.

Key Dates

Keywords

Govorestat, Classic Galactosemia, SORD Deficiency, NDA, MAA, FDA, EMA, PDUFA, Rare Diseases, Biopharmaceutical, Clinical Stage, Accelerated Approval